Market Views – Page 14 – media

Improving health literacy is in pharma’s interests

Patients who understand the information provided about their health are more likely to adhere to a medicine regime and feel empowered to take steps towards healthier lifestyles. To what extent are pharma companies taking the initiative? Amanda Barrell reports.
- Source: PharmaPhorum
- 711
- March 28, 2018
Consumer Healthcare Market Views
Israel to Invest $275 Million in Digital Health Project

Israel approved a plan to invest 1 billion shekels ($275 million) to digitize the personal health records of its nearly 9 million citizens to help develop new drugs.
- Source: Bloomberg
- 574
- March 27, 2018
digital health Market Views
TCR2 Therapeutics Raises $125 Million in Oversubscribed Series B Financing

TCR2 Therapeutics Inc., an immuno-oncology company pioneering a novel class of T cell receptor (TCR)-based cellular therapies for solid tumors and blood cancers, announced today the completion of an oversubscribed Series B financing of $125 million.
- Source: tcr2
- 499
- March 23, 2018
blood cancer Market Views solid tumor TCR
Prothena Announces Global Neuroscience Research & Development Collaboration with Celgene for Novel Therapies for Patients with Neurodegenerative Diseases

Prothena Corporation plc (PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced a global collaboration with Celgene Corporation (CELG) through a subsidiary, to develop new therapies for a broad range of neurodegenerative diseases.
- Source: finance.yahoo
- 477
- March 22, 2018
Market Views neurodegenerative preclinical
Artificial intelligence firm twoXAR raises $10M for partnering drive

Artificial intelligence company twoXAR—a specialist in separating signals from noise in data-rich drug discovery projects—has raised $10 million in a first-round financing led by SoftBank Ventures.
- Source: Fiercebiotech
- 574
- March 22, 2018
diabetes financing Market Views
UNITY Biotechnology, Inc. Completes $55 Million Series C Financing

UNITY Biotechnology, Inc. ("UNITY"), a privately held biotechnology company developing therapeutics to slow, halt or reverse diseases of aging, announced the closing of a $55 million Series C financing.
- Source: prnewswire
- 697
- March 21, 2018
aging Market Views Series
Ionis Pharmaceuticals Partners With Akcea Therapeutics in a Potential $1.7 Billion Deal

In 2017, GlaxoSmithKline ended its partnership with Ionis Pharmaceuticals, Inc. to develop and market inotersen and a follow-up drug for rare diseases. After reviewing its options, Ionis has signed a worldwide license deal to Akcea Therapeutics for inotersen and AKCEA-TTR-LRx in a deal that could hit $1.7 billion. What makes this deal a bit unusual is that Akcea is a subsidiary of Ionis.
- Source: pharmalive
- 564
- March 20, 2018
Akcea-TTR-LRx GlaxoSmithKline Market Views
OWLSTONE MEDICAL RAISES $15 MILLION USD (£11 MILLION GBP) WITH HORIZONS VENTURES AND AVIVA

SBRI Healthcare alumni and Cambridge-based Owlstone Medical has announced that it has raised $15 million (£11 million) to drive the global commercialisation of its Breath Biopsy® platform.
- Source: eahsn.org
- 533
- March 16, 2018
Breath Biopsy® platform lung cancer Market Views
Crinetics Pharmaceuticals Snags $63.5 Million in Series B Funding

Five months after its lead drug began Phase I testing San Diego-based Crinetics Pharmaceuticals Inc has secured $63.5 million in Series B financing.
- Source: biospace
- 412
- March 16, 2018
acromegaly Market Views serise
Cancer Researck UK links with Ideaya on PARG inhibitors

Cancer Research UK is partnering with US biotech Ideaya Biosciences to develop small molecule inhibitors of Poly(ADP-ribose) glycohydrolase (PARG).
- Source: pharmatimes
- 492
- March 15, 2018
glycohydrolase inhibitor Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.